Eli Lilly Inventory 2010-2024 | LLY

Eli Lilly inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
  • Eli Lilly inventory for the quarter ending September 30, 2024 was $7.460B, a 52.2% increase year-over-year.
  • Eli Lilly inventory for 2023 was $5.773B, a 33.95% increase from 2022.
  • Eli Lilly inventory for 2022 was $4.31B, a 10.9% increase from 2021.
  • Eli Lilly inventory for 2021 was $3.886B, a 2.37% decline from 2020.
Eli Lilly Annual Inventory
(Millions of US $)
2023 $5,773
2022 $4,310
2021 $3,886
2020 $3,980
2019 $3,191
2018 $3,098
2017 $4,458
2016 $3,562
2015 $3,446
2014 $2,740
2013 $2,929
2012 $2,644
2011 $2,300
2010 $2,518
2009 $2,850
Eli Lilly Quarterly Inventory
(Millions of US $)
2024-09-30 $7,460
2024-06-30 $6,482
2024-03-31 $6,102
2023-12-31 $5,773
2023-09-30 $4,901
2023-06-30 $4,799
2023-03-31 $4,545
2022-12-31 $4,310
2022-09-30 $3,831
2022-06-30 $3,899
2022-03-31 $3,893
2021-12-31 $3,886
2021-09-30 $3,907
2021-06-30 $3,825
2021-03-31 $3,661
2020-12-31 $3,980
2020-09-30 $3,555
2020-06-30 $3,314
2020-03-31 $3,102
2019-12-31 $3,191
2019-09-30 $3,101
2019-06-30 $3,181
2019-03-31 $3,055
2018-12-31 $3,098
2018-09-30 $4,118
2018-06-30 $4,156
2018-03-31 $4,631
2017-12-31 $4,458
2017-09-30 $4,407
2017-06-30 $4,346
2017-03-31 $4,035
2016-12-31 $3,562
2016-09-30 $3,881
2016-06-30 $3,760
2016-03-31 $3,740
2015-12-31 $3,446
2015-09-30 $3,418
2015-06-30 $3,288
2015-03-31 $2,980
2014-12-31 $2,740
2014-09-30 $2,845
2014-06-30 $3,190
2014-03-31 $2,969
2013-12-31 $2,929
2013-09-30 $2,974
2013-06-30 $2,725
2013-03-31 $2,577
2012-12-31 $2,644
2012-09-30 $2,553
2012-06-30 $2,321
2012-03-31 $2,424
2011-12-31 $2,300
2011-09-30 $2,513
2011-06-30 $2,870
2011-03-31 $2,767
2010-12-31 $2,518
2010-09-30 $2,680
2010-06-30 $2,174
2010-03-31 $2,471
2009-12-31 $2,850
2009-09-30 $3,128
2009-06-30 $3,000
2009-03-31 $2,549
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $789.394B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51